Acute Lymphocytic Leukemia Clinical Trials

13 recruiting

Frequently Asked Questions

Common questions about Acute Lymphocytic Leukemia clinical trials

A clinical trial is a carefully designed research study that tests new medical treatments, drugs, devices, or approaches in human volunteers. Every approved medication and treatment available today was proven safe and effective through clinical trials.

All clinical trials are reviewed and approved by Institutional Review Boards (IRBs) — independent committees that evaluate patient safety. Trials follow strict protocols, and your health is monitored closely throughout. You can withdraw at any time.

Not necessarily. Many trials compare the new treatment against the current standard of care, meaning all participants receive active treatment. When placebos are used, they are typically combined with standard treatment, not given alone. The trial description will always specify the design.

Under the Affordable Care Act, most private insurers are required to cover routine patient care costs during a clinical trial. The sponsor typically covers the investigational treatment itself. Medicare also covers routine costs for qualifying trials.

Yes. Participation is completely voluntary. You can withdraw at any time, for any reason, without it affecting your access to standard medical care.

Each trial has specific eligibility criteria — including age, diagnosis, disease stage, prior treatments, and general health. Browse the trials listed above and check their eligibility sections. You can also contact the trial site directly to discuss your situation.

Showing 120 of 20 trials

Recruiting
Phase 1Phase 2

TCR Reserved and Power3 (SPPL3) Gene Knock-out Allogeneic CD19-targeting CAR-T Cell Therapy in r/r B-ALL

Acute Lymphocytic Leukemia
Chinese PLA General Hospital30 enrolled6 locationsNCT06481735
Recruiting
Phase 1Phase 2

CD19/CD22 Bicistronic Chimeric Antigen Receptor (CAR) T Cells in Children and Young Adults With Recurrent or Refractory CD19/CD22-expressing B Cell Malignancies

Acute Lymphoblastic LeukemiaLymphoma, Non-HodgkinB-cell Lymphoma+8 more
National Cancer Institute (NCI)126 enrolled1 locationNCT05442515
Recruiting
Not Applicable

Umbilical Cord Blood Transplantation Using a Myeloablative Preparative Regimen for Hematological Diseases

Diffuse Large B Cell LymphomaChronic Lymphocytic LeukemiaNon-Hodgkin Lymphoma+15 more
Masonic Cancer Center, University of Minnesota200 enrolled1 locationNCT01962636
Recruiting
Phase 1Phase 2

CD5 Chimeric Antigen Receptor (CAR) T Cells in Subjects With Relapsed or Refractory T-cell Malignancies

Acute Lymphoblastic Leukemia, in RelapseRefractory Acute Lymphoblastic LeukemiaT-cell Malignancies+1 more
Beijing GoBroad Hospital54 enrolled4 locationsNCT06316856
Recruiting
Phase 1

Pilot Imaging Study of Leukemia

Acute Myeloid LeukemiaMyelomaAcute Lymphocytic Leukemia+1 more
University of Oklahoma60 enrolled3 locationsNCT03633955
Recruiting
Phase 2

Co-Transplant of an Unmodified Haplo-Identical Graft With Cord Blood

Acute Myelogenous LeukemiaMyelodysplastic SyndromesAcute Lymphocytic Leukemia+1 more
Case Comprehensive Cancer Center36 enrolled1 locationNCT06904482
Recruiting
Phase 2

Phase 2 Study Assessing the Clinical Activity and Safety of Obecabtagene Autoleucel as a Consolidation in Patients With Newly Diagnosed High-risk B-cell Acute Lymphocytic Leukemia (ALL)

Acute Lymphocytic Leukemia (ALL)
M.D. Anderson Cancer Center30 enrolled1 locationNCT07053059
Recruiting

Pharmacokinetic Study of Venetoclax Tablets Crushed and Dissolved Into a Solution

Diffuse Large B Cell LymphomaHodgkin LymphomaNon-Hodgkin Lymphoma+16 more
Children's Hospital Medical Center, Cincinnati30 enrolled5 locationsNCT06131801
Recruiting
Phase 1Phase 2

Phase Ib/II Study Assessing the Clinical Activity and Safety of Brexucabtagene Autoleucel as a Consolidation in Patients With Relapsed/Refractory (R/R) and Newly Diagnosed B-cell Acute Lymphocytic Leukemia (ALL) Post Cytoreduction With Mini-HCVD-inotuzumab-blinatumomab/HCVAD-inotuzumab-blinatumomab

Relapsed/RefractoryB-cell Acute Lymphocytic Leukemia
M.D. Anderson Cancer Center40 enrolled1 locationNCT06287229
Recruiting
Phase 1Phase 2

A Study of CTD402 in T-ALL/LBL Patients

Lymphoma, LymphoblasticAcute Lymphocytic Leukemia Refractory
BIOHENG THERAPEUTICS US LLC54 enrolled8 locationsNCT07070219
Recruiting
Phase 1Phase 2

Tafasitamab (MOR00208) in Pediatric Patients With Relapsed or Refractory Acute B Lineage Leukemia

ALL, Childhood B-CellAcute Lymphoid Leukemia RelapseAcute Lymphocytic Leukemia Refractory
University Hospital Tuebingen20 enrolled11 locationsNCT05366218
Recruiting
Phase 1

Activated T-Cells Expressing 2nd or 3rd Generation CD19-Specific CAR, Advanced B-Cell NHL, ALL, and CLL (SAGAN)

Chronic Lymphocytic LeukemiaNon-Hodgkin LymphomaAcute Lymphocytic Leukemia
Baylor College of Medicine64 enrolled2 locationsNCT01853631
Recruiting

The Prospective Collection, Storage and Reporting of Data on Patients Undergoing Hematopoietic Stem Cell Transplantation Utilizing a Standard Preparative Regimen

Chronic Lymphocytic LeukemiaMultiple MyelomaAcute Myelogenous Leukemia+7 more
Wake Forest University Health Sciences2,000 enrolled1 locationNCT01890486
Recruiting
Phase 1Phase 2

Safety and Efficacy of Ponatinib for Treatment of Pediatric Recurrent or Refractory Leukemias, Lymphomas or Solid Tumors

Solid TumorsAcute Lymphoblastic LeukemiaAcute Myeloid Leukemia+6 more
Incyte Biosciences International Sàrl70 enrolled25 locationsNCT03934372
Recruiting
Phase 1Phase 2

A Multicenter, Open-Label, Non-Randomized, Single-Arm Clinical Study of Nanobody CD5-CAR T Cell Therapy for Refractory/Relapsed T Lymphocyte Malignancies

Acute Lymphoblastic Leukemia, in RelapseRefractory Acute Lymphoblastic LeukemiaT-cell Malignancies+1 more
Beijing GoBroad Hospital54 enrolled4 locationsNCT07070323
Recruiting
Phase 2

Allo HSCT Using RIC and PTCy for Hematological Diseases

Acute Myelogenous LeukemiaMyelodysplastic SyndromesLeukemia, Myeloid+15 more
Masonic Cancer Center, University of Minnesota56 enrolled1 locationNCT05805605
Recruiting
Phase 1Phase 2

BCOR and ZC3H12 Genes Knock-out CD19-targeting CAR-T Cell Therapy in r/r B-ALL

Acute Lymphocytic Leukemia
Chinese PLA General Hospital30 enrolled2 locationsNCT07008885
Recruiting
Phase 1Phase 2

Inotuzumab Ozogamicin Post-Transplant For Acute Lymphocytic Leukemia

Acute Lymphocytic Leukemia
Leland Metheny44 enrolled7 locationsNCT03104491
Recruiting
Not Applicable

A Novel CAR-T Combined Expression of IL-15 in the Treatment of Malignant Hematological Tumors

Lymphoma, Non-HodgkinAcute Lymphocytic LeukemiaRelapsed/Refractory Multiple Myeloma
Shanxi Bethune Hospital45 enrolled1 locationNCT06783816
Recruiting
Phase 1

Study of Oral Administration of LP-118 in Patients With Relapsed or Refractory CLL, SLL, MDS, MDS/MPN, AML, CMML-2, MPN-BP, ALL, MF, NHL, RT, MM or T-PLL.

Acute Myeloid LeukemiaChronic Lymphocytic LeukemiaNon-Hodgkin Lymphoma+10 more
Newave Pharmaceutical Inc100 enrolled8 locationsNCT04771572